1. Home
  2. IRIX vs CVKD Comparison

IRIX vs CVKD Comparison

Compare IRIX & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IRIDEX Corporation

IRIX

IRIDEX Corporation

HOLD

Current Price

$1.51

Market Cap

24.2M

Sector

Health Care

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$6.97

Market Cap

20.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRIX
CVKD
Founded
1989
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.2M
20.7M
IPO Year
1996
2023

Fundamental Metrics

Financial Performance
Metric
IRIX
CVKD
Price
$1.51
$6.97
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$32.00
AVG Volume (30 Days)
105.1K
55.5K
Earning Date
11-11-2025
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,647,000.00
N/A
Revenue This Year
$9.61
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.58
N/A
52 Week Low
$0.78
$6.42
52 Week High
$1.72
$22.90

Technical Indicators

Market Signals
Indicator
IRIX
CVKD
Relative Strength Index (RSI) 70.64 40.26
Support Level $1.22 $6.55
Resistance Level $1.54 $8.79
Average True Range (ATR) 0.11 0.58
MACD 0.03 0.11
Stochastic Oscillator 88.65 31.27

Price Performance

Historical Comparison
IRIX
CVKD

About IRIX IRIDEX Corporation

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: